Front-Loading Drug Development: Q&A with Revalia Bio's Jenna DiRito
In Applied Clinical Trials, Jenna DiRito, PhD — COO and co-founder of Pamir Ventures portfolio company Revalia Bio — discusses how earlier, human-relevant data is reshaping go/no-go decision-making in drug development, and what a genuinely front-loaded workflow looks like in practice.
The conventional pipeline pushes the most decisive evidence — how a therapy behaves in humans — to its most expensive stage. DiRito makes the case for inverting that: bring human data forward, kill the losers early, and concentrate resources on the candidates that earn them.
It's the operating philosophy behind Revalia's human-data-trials platform, and a preview of how the company thinks about the next generation of preclinical evidence.